Results 81 to 90 of about 5,617 (179)

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Annals of Neurology, Volume 98, Issue 2, Page 317-328, August 2025.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr., Bruce A. C. Cree, Stephen L. Hauser   +2 more
wiley   +1 more source

“You Can Rest Knowing That We Know What You Want”—Longitudinal Advance Care Planning Discussions With Young Adults Receiving Hematopoietic Stem Cell Transplantation

Psycho-Oncology, Volume 34, Issue 6, June 2025.
ABSTRACT Objective Young adults (YAs) undergoing hematopoietic stem cell transplantation (HSCT) often face significant transplant‐related morbidity and mortality. Advance care planning (ACP) discussions can provide YAs with the opportunity to address treatment goals and care preferences with their family members and healthcare team.
Anna Katharina Vokinger, Brian Pennarola, Paige Kube, Devon Ciampa, Gisela Michel, Jennifer Hendricks, Brigit Rweikiza, Sara K. Silbert, Lori Wiener   +8 more
wiley   +1 more source

X-Linked Agammaglobulinemia with Kawasaki Disease [PDF]

Indian Journal of Pediatrics, 2022
Sakshi Shakya, Anu Maheshwari, Kakarla Divya, Bharat Ravi Katti, Ackshaya R, Deonath Mahto   +5 more
openaire   +2 more sources

Use of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Combined With Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19‐9 in Predicting Colorectal Cancer Liver Metastasis

Journal of Clinical Ultrasound, Volume 53, Issue 4, Page 612-619, May 2025.
The study subjects were mainly CRC patients (n = 120), all of whom underwent the same comprehensive treatment regimen and were divided into the effective treatment group (n = 86) and the ineffective treatment group (n = 34) according to efficacy after treatment.
Hong‐Bo Ji, Bo Qian, Jian‐Jun Hu, Wei Qi, Zi‐Gang Che   +4 more
wiley   +1 more source

Beyond TREC: Pivotal role of tandem TREC/KREC assay in Czech SCID NBS pilot programme

Pediatric Allergy and Immunology, Volume 36, Issue 5, May 2025.
Abstract Background Severe combined immunodeficiency (SCID) is a fatal but treatable inborn error of immunity (IEI). Newborn screening (NBS) using T‐cell receptor excision circles (TREC) has been adopted globally, with very few countries incorporating kappa recombination excision circles (KREC) to also detect early B‐cell development disorders, such as
Markéta Bloomfield, Eva Hlaváčková, Helena Schneiderová, Marek Turnovec, Lukáš Tichý, Zbyněk Čech, Petr Chrastina, Lenka Dvořáková, Karolína Pešková, Renata Formánková, Petr Říha, Marcela Vlková, Petr Bejdák, Magdaléna Havlišová, Eva Froňková, Tomáš Kalina, Viktor Bíly, Dita Říčná, Hana Grombiříková, Petr Sedláček, Jiří Litzman, Tomáš Freiberger, Anna Šedivá, Adam Klocperk   +23 more
wiley   +1 more source

Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis)

Iranian Journal of Allergy, Asthma and Immunology, 2020
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by genetic defects in the Bruton tyrosine kinase (Btk) gene. XLA is characterized as an antibody deficiency by recurrent bacterial infections, the absence of peripheral B cells, and ...
Zahra Alizadeh, Parisa Dashti, Marzieh Mazinani, Maryam Nourizadeh, Leila Shakerian, Shaghayegh Tajik, Masoud Movahedi, Setareh Mamishi, Zahra Pourpak, Mohammad Reza Fazlollahi   +9 more
doaj   +1 more source

X-linked agammaglobulinemia - first case with bruton tyrosine kinase mutation from Pakistan [PDF]

, 2017
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase (Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.
Zaidi, Samreen Kulsom, Qamar, Farah Naz, Qureshi, Sonia   +2 more
core   +1 more source

X-Linked Agammaglobulinemia A Clinical and Molecular Analysis

Medicine, 1996
X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of B lymphocytes due to an arrest in B lymphocyte development, is caused by mutations in the gene encoding Btk (Bruton tyrosine kinase). The BTK gene has been cloned and the genomic organization determined.
H D, Ochs, C I, Smith
openaire   +2 more sources

Atypical Manifestation of X-linked Agammaglobulinemia – the Importance of Genetic Testing

Acta Medica
X-linked agammaglobulinemia (XLA) was one of the first inborn errors of immunity to be described. It is caused by pathogenic variants in the gene for Bruton tyrosine kinase (BTK), which has important functions in B cell development and maturation ...
Adam Markocsy, Daniela Kapustová, Andrej Čereš, Eva Froňková, Miloš Jeseňák   +4 more
doaj   +1 more source

Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults

Respiratory Research, 2001
Background X-linked agammaglobulinemia (XLA) is a humoral immunodeficiency caused by disruption of the Bruton's tyrosine kinase (BTK) gene. Typical XLA patients suffer recurrent and severe bacterial infections in childhood.
Tsuchiya Shigeru, Miyawaki Toshio, Tsukada Satoshi, Hagiwara Koichi, Tazawa Ryushi, Sasahara Yoji, Usui Kazuhiro, Nukiwa Toshihiro   +7 more
doaj   +1 more source